You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNitrazepam
Accession NumberDB01595
TypeSmall Molecule
GroupsApproved
DescriptionA benzodiazepine derivative used as an anticonvulsant and hypnotic.
Structure
Thumb
Synonyms
1,3-dihydro-7-Nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
2,3-dihydro-7-Nitro-5-phenyl-1H-1,4-benzodiazepin-2-one
7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
Apodorm
Atempol
Benzalin
Calsmin
Eatan
Eunoctin
Gerson
Hipnax
Hipsal
Ibrovek
Imeson
Imesont
Mogadon
N-Desmethylnimetazepam
Nelbon
Nelmat
Neozepam
Neuchlonic
Nitrados
Nitrazepamum
Paxisyn
Pelson
Persopit
Radedorm
Relact
Remnos
Ro 4-5360
Ro 5-3059
Somitran
Sonebon
Sonnolin
Surem
Trazenin
Unisomnia
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mogadontablet5 mgoralAa Pharma Inc1980-12-31Not applicableCanada
Mogadontablet10 mgoralAa Pharma Inc1980-12-31Not applicableCanada
Nitrazadontablet5 mgoralAa Pharma Inc1996-11-082014-06-25Canada
Nitrazadontablet10 mgoralAa Pharma Inc1996-11-082014-06-25Canada
Nitrazepam-10tablet10 mgoralPro Doc Limitee2004-07-292010-07-13Canada
Nitrazepam-5tablet5 mgoralPro Doc Limitee2004-07-292010-07-13Canada
Sandoz Nitrazepamtablet5 mgoralSandoz Canada Incorporated1997-12-02Not applicableCanada
Sandoz Nitrazepamtablet10 mgoralSandoz Canada Incorporated1997-12-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nitrazepam Tablets BPtablet5 mgoralApotex Inc2002-09-17Not applicableCanada
Apo-nitrazepam Tablets BPtablet10 mgoralApotex Inc2002-09-17Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlodormNot Available
AremNot Available
BenzalinNot Available
InsomaNot Available
NitradosNot Available
NitrosunNot Available
OrmodonNot Available
PacisynNot Available
PaxadormNot Available
RemnosNot Available
SomniteNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9CLV70W7HS
CAS number146-22-5
WeightAverage: 281.2661
Monoisotopic: 281.080041233
Chemical FormulaC15H11N3O3
InChI KeyInChIKey=KJONHKAYOJNZEC-UHFFFAOYSA-N
InChI
InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)
IUPAC Name
7-nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Benzenoid
  • Monocyclic benzene moiety
  • Organic nitro compound
  • Secondary carboxylic acid amide
  • Organic nitrite
  • C-nitro compound
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Imine
  • Carbonyl group
  • Organic zwitterion
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.
PharmacodynamicsNitrazepam is a type of benzodiazepine drug. It is a powerful hypnotic drug which possesses strong sedative, anxiolytic, amnestic, anticonvulsant, and skeletal muscle relaxant properties. Nitrazepam shortens the time required to fall asleep and lengthens the duration of sleep. It is also useful for the management of myoclonic seizures.
Mechanism of actionNitrazepam belongs to a group of medicines called benzodiazepines. It acts on benzodiazepine receptors in the brain which are associated with the GABA receptors causing an enhanced binding of GABA (gamma amino butyric acid) to GABAA receptors. GABA is a major inhibitory neurotransmitter in the brain, involved in inducing sleepiness, muscular relaxation and control of anxiety and fits, and slows down the central nervous system. The anticonvulsant properties of nitrazepam and other benzodiazepines may be in part or entirely due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.
Related Articles
AbsorptionBioavailability is 53-94% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life15-38 hours (mean elimination half life 26 hours).
ClearanceNot Available
ToxicityNitrazepam is a drug which is very frequently involved in drug intoxication, including overdose. Nitrazepam overdose may result in stereotypical symptoms of benzodiazepine overdose including intoxication, impaired balance, slurred speech. In cases of severe overdose this may progress to a comatose state with the possibility of death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9802
Caco-2 permeable+0.5176
P-glycoprotein substrateSubstrate0.5785
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9205
Renal organic cation transporterNon-inhibitor0.8307
CYP450 2C9 substrateNon-substrate0.7695
CYP450 2D6 substrateNon-substrate0.8583
CYP450 3A4 substrateSubstrate0.6725
CYP450 1A2 substrateInhibitor0.7569
CYP450 2C9 inhibitorNon-inhibitor0.6133
CYP450 2D6 inhibitorNon-inhibitor0.8986
CYP450 2C19 inhibitorInhibitor0.5682
CYP450 3A4 inhibitorInhibitor0.6791
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5645
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7197
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9904
hERG inhibition (predictor II)Non-inhibitor0.8498
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Mogadon 10 mg Tablet0.24USD tablet
Mogadon 5 mg Tablet0.16USD tablet
Apo-Nitrazepam 10 mg Tablet0.13USD tablet
Nitrazadon 10 mg Tablet0.11USD tablet
Sandoz Nitrazepam 10 mg Tablet0.11USD tablet
Apo-Nitrazepam 5 mg Tablet0.09USD tablet
Nitrazadon 5 mg Tablet0.08USD tablet
Sandoz Nitrazepam 5 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point225 °CPhysProp
logP2.25HANSCH,C ET AL. (1995)
logS-3.8ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0299 mg/mLALOGPS
logP1.95ALOGPS
logP2.55ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.9ChemAxon
pKa (Strongest Basic)2.61ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.28 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity79.22 m3·mol-1ChemAxon
Polarizability27.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0zgi-2490000000-84b5bf7df62c745f8414View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis ReferenceNot Available
General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. [PubMed:7782744 ]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  4. Podhorna J, Krsiak M: Behavioural effects of a benzodiazepine receptor partial agonist, Ro 19-8022, in the social conflict test in mice. Behav Pharmacol. 2000 Apr;11(2):143-51. [PubMed:10877119 ]
  5. Nowakowska E, Chodera A: Studies on the involvement of opioid mechanism in the locomotor effects of benzodiazepines in rats. Pharmacol Biochem Behav. 1991 Feb;38(2):265-6. [PubMed:1676167 ]
External Links
ATC CodesN05CD02
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with 7-Nitroindazole.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Nitrazepam.
AcepromazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Nitrazepam.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nitrazepam.
adipiplonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nitrazepam.
AgomelatineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nitrazepam.
AlfaxaloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nitrazepam.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nitrazepam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Nitrazepam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nitrazepam.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Nitrazepam.
AminophyllineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Nitrazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nitrazepam.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nitrazepam.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nitrazepam.
AmoxapineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amperozide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nitrazepam.
AprepitantThe serum concentration of Nitrazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrazepam.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrazepam.
ArticaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Asenapine.
AtazanavirThe metabolism of Nitrazepam can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Nitrazepam.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Nitrazepam.
AtomoxetineThe metabolism of Nitrazepam can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nitrazepam.
AzaperoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Azaperone.
AzelastineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nitrazepam.
BaclofenThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Nitrazepam.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nitrazepam.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nitrazepam.
BexaroteneThe serum concentration of Nitrazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Nitrazepam can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Nitrazepam.
BortezomibThe metabolism of Nitrazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nitrazepam can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nitrazepam.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrazepam.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nitrazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrazepam.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nitrazepam.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrazepam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrazepam.
ButacaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Nitrazepam.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrazepam.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrazepam.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Nitrazepam.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nitrazepam.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Nitrazepam.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Nitrazepam.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nitrazepam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Nitrazepam.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nitrazepam.
CarisoprodolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carisoprodol.
CeritinibThe serum concentration of Nitrazepam can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nitrazepam.
CetirizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nitrazepam.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nitrazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Nitrazepam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nitrazepam.
ChlorphenamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Nitrazepam.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrazepam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nitrazepam.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorzoxazone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Nitrazepam.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nitrazepam.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nitrazepam.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nitrazepam.
CitalopramThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Citalopram.
ClarithromycinThe metabolism of Nitrazepam can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Nitrazepam.
ClemastineThe metabolism of Nitrazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nitrazepam.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Nitrazepam.
clomethiazoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nitrazepam.
ClomipramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Nitrazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitrazepam.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Nitrazepam.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrazepam.
ClotrimazoleThe metabolism of Nitrazepam can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Nitrazepam.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nitrazepam.
CobicistatThe metabolism of Nitrazepam can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nitrazepam.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Nitrazepam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Nitrazepam.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nitrazepam.
ConivaptanThe serum concentration of Nitrazepam can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nitrazepam.
CosyntropinCosyntropin may increase the hepatotoxic activities of Nitrazepam.
CrizotinibThe metabolism of Nitrazepam can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nitrazepam.
CyclizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrazepam.
CyclosporineThe metabolism of Nitrazepam can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nitrazepam.
CyproheptadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nitrazepam.
DabrafenibThe serum concentration of Nitrazepam can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Nitrazepam.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nitrazepam.
DantroleneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrazepam.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nitrazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapoxetine.
DarunavirThe metabolism of Nitrazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Nitrazepam can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nitrazepam.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nitrazepam.
DeferasiroxThe serum concentration of Nitrazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Nitrazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrazepam.
DesipramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Nitrazepam can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Nitrazepam.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrazepam.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Nitrazepam.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nitrazepam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Nitrazepam.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nitrazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nitrazepam.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nitrazepam.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nitrazepam.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrazepam.
DihydroergotamineThe metabolism of Nitrazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nitrazepam.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nitrazepam.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrazepam.
DiltiazemThe metabolism of Nitrazepam can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Nitrazepam.
DimenhydrinateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nitrazepam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nitrazepam.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Nitrazepam.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nitrazepam.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nitrazepam.
DoramectinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nitrazepam.
DoxycyclineThe metabolism of Nitrazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Nitrazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
DronedaroneThe metabolism of Nitrazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Nitrazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Nitrazepam.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrazepam.
DyphyllineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Nitrazepam.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Nitrazepam is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nitrazepam.
EfavirenzThe serum concentration of Nitrazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nitrazepam.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Nitrazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Nitrazepam can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nitrazepam.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nitrazepam.
ErythromycinThe metabolism of Nitrazepam can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Nitrazepam.
EscitalopramThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Nitrazepam can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Nitrazepam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nitrazepam.
EstriolThe serum concentration of Estriol can be increased when it is combined with Nitrazepam.
EstroneThe serum concentration of Estrone can be increased when it is combined with Nitrazepam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nitrazepam.
EthanolNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Nitrazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nitrazepam.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nitrazepam.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nitrazepam.
EtidocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Nitrazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nitrazepam.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Nitrazepam.
EtravirineThe serum concentration of Nitrazepam can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nitrazepam.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nitrazepam.
EzogabineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Nitrazepam.
FenfluramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrazepam.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Nitrazepam.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nitrazepam.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Nitrazepam.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nitrazepam.
FlibanserinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flibanserin.
FluconazoleThe metabolism of Nitrazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nitrazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrazepam.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrazepam.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Nitrazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Nitrazepam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nitrazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Nitrazepam.
FospropofolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Nitrazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrazepam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Nitrazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Nitrazepam.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nitrazepam.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nitrazepam.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Nitrazepam.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nitrazepam.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nitrazepam.
GuanfacineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Nitrazepam.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Nitrazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrazepam.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nitrazepam.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Nitrazepam.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Nitrazepam.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nitrazepam.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nitrazepam.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nitrazepam.
IdelalisibThe serum concentration of Nitrazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Iloperidone.
ImatinibThe metabolism of Nitrazepam can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nitrazepam.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nitrazepam.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitrazepam.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nitrazepam.
IndalpineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Indalpine.
IndinavirThe metabolism of Nitrazepam can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Nitrazepam.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Nitrazepam.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nitrazepam.
IsavuconazoniumThe metabolism of Nitrazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrazepam.
IsradipineThe metabolism of Nitrazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Nitrazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Nitrazepam can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nitrazepam.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrazepam.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nitrazepam.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nitrazepam.
KetobemidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ketobemidone.
KetoconazoleThe metabolism of Nitrazepam can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Nitrazepam.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nitrazepam.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nitrazepam.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Nitrazepam.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nitrazepam.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nitrazepam.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nitrazepam.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Nitrazepam.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nitrazepam.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Nitrazepam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrazepam.
LevocabastineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nitrazepam.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nitrazepam.
LevomilnacipranThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nitrazepam.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Nitrazepam.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nitrazepam.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Nitrazepam.
LofentanilThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nitrazepam.
LopinavirThe metabolism of Nitrazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nitrazepam.
LosartanThe serum concentration of Losartan can be increased when it is combined with Nitrazepam.
LovastatinThe metabolism of Nitrazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nitrazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Nitrazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Nitrazepam can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Nitrazepam.
MaprotilineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Nitrazepam.
MelperoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nitrazepam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrazepam.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nitrazepam.
MetaxaloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Metaxalone.
MethadoneNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Nitrazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Nitrazepam.
MethapyrileneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Nitrazepam.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nitrazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Nitrazepam.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nitrazepam.
MethsuximideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Nitrazepam.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrazepam.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nitrazepam.
MetyrosineNitrazepam may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mianserin.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nitrazepam.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nitrazepam.
MifepristoneThe metabolism of Nitrazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nitrazepam.
MirtazapineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nitrazepam.
MitotaneThe serum concentration of Nitrazepam can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nitrazepam.
ModafinilThe serum concentration of Nitrazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Nitrazepam.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrazepam.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrazepam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
NabiloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Nitrazepam.
NafcillinThe serum concentration of Nitrazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nitrazepam.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nitrazepam.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Nitrazepam.
NefazodoneThe metabolism of Nitrazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Nitrazepam can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Nitrazepam.
NetupitantThe serum concentration of Nitrazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Nitrazepam can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Nitrazepam.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Nitrazepam.
NilotinibThe metabolism of Nitrazepam can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Nitrazepam.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nitrazepam.
NormethadoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrazepam.
OlaparibThe metabolism of Nitrazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nitrazepam.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Nitrazepam.
OpiumThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Opium.
OrlistatThe serum concentration of Nitrazepam can be decreased when it is combined with Orlistat.
OrphenadrineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Nitrazepam.
OsanetantThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Osanetant.
OsimertinibThe serum concentration of Nitrazepam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nitrazepam.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nitrazepam.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nitrazepam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nitrazepam.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nitrazepam.
PalbociclibThe serum concentration of Nitrazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrazepam.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nitrazepam.
ParaldehydeNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Nitrazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nitrazepam.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nitrazepam.
PerampanelThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrazepam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nitrazepam.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Nitrazepam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nitrazepam.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nitrazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Nitrazepam.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Nitrazepam.
PipamperoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nitrazepam.
PizotifenThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nitrazepam.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Nitrazepam.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nitrazepam.
PosaconazoleThe metabolism of Nitrazepam can be decreased when combined with Posaconazole.
PramipexoleNitrazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nitrazepam.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Nitrazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Nitrazepam.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nitrazepam.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nitrazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nitrazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Nitrazepam.
PrimidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Nitrazepam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrazepam.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Nitrazepam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrazepam.
PromethazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nitrazepam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrazepam.
PropoxycaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Nitrazepam.
ProtriptylineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nitrazepam.
PSD502The risk or severity of adverse effects can be increased when Nitrazepam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Nitrazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Nitrazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrazepam.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Nitrazepam.
QuinineThe serum concentration of Quinine can be increased when it is combined with Nitrazepam.
RamelteonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nitrazepam.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nitrazepam.
RanolazineThe metabolism of Nitrazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrazepam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nitrazepam.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Nitrazepam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitrazepam.
RifabutinThe metabolism of Nitrazepam can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Nitrazepam can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Nitrazepam.
RifapentineThe metabolism of Nitrazepam can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nitrazepam.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Nitrazepam.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Nitrazepam.
RitonavirThe metabolism of Nitrazepam can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Nitrazepam.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrazepam.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nitrazepam.
RomifidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Romifidine.
RopiniroleNitrazepam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrazepam.
RotigotineNitrazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nitrazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Nitrazepam is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Nitrazepam.
SaquinavirThe metabolism of Nitrazepam can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Nitrazepam.
ScopolamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrazepam.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Nitrazepam.
SertindoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrazepam.
SildenafilThe metabolism of Nitrazepam can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nitrazepam.
SiltuximabThe serum concentration of Nitrazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nitrazepam can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nitrazepam.
Sodium oxybateNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Nitrazepam.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nitrazepam.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nitrazepam.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nitrazepam.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nitrazepam.
St. John's WortThe serum concentration of Nitrazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.
SulfisoxazoleThe metabolism of Nitrazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nitrazepam.
SuvorexantThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nitrazepam.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nitrazepam.
TapentadolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nitrazepam.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nitrazepam.
TeduglutideThe serum concentration of Nitrazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Nitrazepam can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Nitrazepam.
TelithromycinThe metabolism of Nitrazepam can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nitrazepam.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nitrazepam.
TetrabenazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrodotoxin.
ThalidomideNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nitrazepam.
TheophyllineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nitrazepam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Nitrazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitrazepam.
ThiothixeneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nitrazepam.
TiclopidineThe metabolism of Nitrazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Nitrazepam.
TizanidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Nitrazepam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nitrazepam.
TopiramateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nitrazepam.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Nitrazepam.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nitrazepam.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nitrazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Nitrazepam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrazepam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nitrazepam.
TrimipramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nitrazepam.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nitrazepam.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Nitrazepam.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nitrazepam.
VenlafaxineThe metabolism of Nitrazepam can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Nitrazepam.
VerapamilThe metabolism of Nitrazepam can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Nitrazepam.
VigabatrinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nitrazepam.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nitrazepam.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nitrazepam.
VoriconazoleThe metabolism of Nitrazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrazepam.
ZiconotideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nitrazepam.
ZimelidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Nitrazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Nitrazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Nitrazepam.
ZotepineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  3. Podhorna J, Krsiak M: Behavioural effects of a benzodiazepine receptor partial agonist, Ro 19-8022, in the social conflict test in mice. Behav Pharmacol. 2000 Apr;11(2):143-51. [PubMed:10877119 ]
  4. Tanaka M, Suemaru K, Watanabe S, Cui R, Li B, Araki H: Comparison of short- and long-acting benzodiazepine-receptor agonists with different receptor selectivity on motor coordination and muscle relaxation following thiopental-induced anesthesia in mice. J Pharmacol Sci. 2008 Jul;107(3):277-84. Epub 2008 Jul 5. [PubMed:18603831 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN1A
Uniprot ID:
P35498
Molecular Weight:
228969.49 Da
References
  1. McLean MJ, Macdonald RL: Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. J Pharmacol Exp Ther. 1988 Feb;244(2):789-95. [PubMed:2450203 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 11:49 / Updated on August 17, 2016 12:23